No, You Should Not Take Carvedilol and Metoprolol Together
Do not combine carvedilol and metoprolol—using two beta-blockers from the same class simultaneously is contraindicated and provides no additional benefit while significantly increasing the risk of adverse effects including severe bradycardia, heart block, hypotension, and worsening heart failure.
Why This Combination Is Harmful
The 2017 ACC/AHA Hypertension Guidelines explicitly state that "2 drugs from the same class should not be administered together (e.g., 2 different beta blockers)" 1, 2, 3. Both carvedilol and metoprolol are beta-adrenergic blocking agents that work through similar mechanisms—blocking beta-receptors in the heart and blood vessels. Combining them creates:
- Excessive beta-blockade leading to dangerously slow heart rates (severe bradycardia)
- Additive negative inotropic effects that can precipitate or worsen heart failure
- Compounded risk of heart block, particularly in patients with pre-existing conduction abnormalities
- Severe hypotension from overlapping blood pressure-lowering effects
- No additional therapeutic benefit since both drugs target the same receptors
Choosing Between Carvedilol and Metoprolol
If you need to optimize beta-blocker therapy, choose one agent and titrate to target dose rather than combining two:
For Heart Failure with Reduced Ejection Fraction (HFrEF):
Use carvedilol, metoprolol succinate (extended-release), or bisoprolol—these are the only beta-blockers proven to reduce mortality in heart failure 4, 5. Among these:
- Carvedilol (target: 25-50 mg twice daily) offers additional alpha-1 blockade and vasodilation 4, 5
- Metoprolol succinate (target: 200 mg once daily) is beta-1 selective 4, 5
- One study (COMET) showed carvedilol reduced mortality more than metoprolol tartrate, though this may relate to the short-acting formulation used 6
For Hypertension or Ischemic Heart Disease:
Either agent is acceptable, but carvedilol may provide superior blood pressure reduction due to its vasodilatory properties 7, 8, 9. The 2018 guidelines note both are effective, with bisoprolol and metoprolol succinate preferred in HFrEF 1, 2.
For Patients with ICDs or Ventricular Arrhythmias:
Recent evidence suggests carvedilol may reduce inappropriate ICD shocks (35% reduction) and atrial tachyarrhythmias compared to metoprolol 10, 11, though one study showed higher composite arrhythmic endpoints with carvedilol 12.
If You Need to Switch Beta-Blockers
The COMET post-study phase demonstrated that switching between beta-blockers is safe when done properly 13:
- Start the new beta-blocker at 50% of the equivalent dose of the previous agent
- Gradually titrate upward over weeks to target dose
- Monitor closely for bradycardia, hypotension, and heart failure symptoms
- Patients switching from carvedilol to metoprolol had higher event rates (12.3% vs 3.1%) than those switching to carvedilol 13
Critical Drug Interactions to Avoid
The FDA label for carvedilol warns about combining beta-blockers with 14:
- Non-dihydropyridine calcium channel blockers (diltiazem, verapamil): Risk of severe bradycardia and heart block 1, 3
- Amiodarone: Increases carvedilol levels 2-fold, enhancing beta-blocking effects 14
- Digoxin: Both drugs slow AV conduction; monitor for excessive bradycardia 14
Common Pitfalls
- Using metoprolol tartrate instead of succinate for heart failure: Only the extended-release succinate formulation has mortality benefit 15, 5
- Combining beta-blockers with other negative chronotropes: Avoid routine use with non-dihydropyridine CCBs 1, 16
- Abrupt discontinuation: Both drugs require gradual tapering to avoid rebound hypertension and ischemia 1, 14
Bottom line: Select one beta-blocker based on your specific indication, titrate it to target dose, and never combine two beta-blockers simultaneously.